NasdaqCM - Delayed Quote USD

Genelux Corporation (GNLX)

Compare
2.5500 +0.0300 (+1.19%)
At close: October 25 at 4:00 PM EDT
Loading Chart for GNLX
DELL
  • Previous Close 2.5200
  • Open 2.5300
  • Bid --
  • Ask --
  • Day's Range 2.4300 - 2.5750
  • 52 Week Range 1.6000 - 18.0100
  • Volume 56,996
  • Avg. Volume 152,815
  • Market Cap (intraday) 88.066M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.50

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

www.genelux.com

24

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GNLX

View More

Performance Overview: GNLX

Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNLX
81.80%
S&P 500
21.77%

1-Year Return

GNLX
87.03%
S&P 500
36.74%

3-Year Return

GNLX
57.50%
S&P 500
43.04%

5-Year Return

GNLX
57.50%
S&P 500
43.04%

Compare To: GNLX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GNLX

View More

Valuation Measures

Annual
As of 10/25/2024
  • Market Cap

    88.07M

  • Enterprise Value

    56.64M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.74k

  • Price/Book (mrq)

    2.34

  • Enterprise Value/Revenue

    7.08k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -44.61%

  • Return on Equity (ttm)

    -88.57%

  • Revenue (ttm)

    8k

  • Net Income Avi to Common (ttm)

    -26.54M

  • Diluted EPS (ttm)

    -0.9500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    33.64M

  • Total Debt/Equity (mrq)

    5.86%

  • Levered Free Cash Flow (ttm)

    -11.9M

Research Analysis: GNLX

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 8k
Earnings -7.85M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

10.00
21.50 Average
2.5500 Current
32.00 High
 

Company Insights: GNLX

People Also Watch